Facebook Linkedin RSS Twitter Youtube
Home 2024

WuXi Biologics

Strategies for Developing and Manufacturing Bispecific Antibodies and Fusion Proteins
Multimedia

Strategies for Developing and Manufacturing Bispecific Antibodies and Fusion Proteins

StockWatch: Chinese Biotechs Targeted by BIOSECURE Act Rise after House Committee Setback
Drug Discovery

StockWatch: Chinese Biotechs Targeted by BIOSECURE Act Rise after House Committee Setback

“Talent, Talent, Talent” Drives Fujifilm Diosynth’s $3.2B NC Expansion
Bioprocessing

“Talent, Talent, Talent” Drives Fujifilm Diosynth’s $3.2B NC Expansion

WuXi Biologics Boosts Manufacturing Capability with Installation of Three 5,000L Single-Use Bioreactors
Bioprocessing

WuXi Biologics Boosts Manufacturing Capability with Installation of Three 5,000L Single-Use Bioreactors

StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs
Bioprocessing

StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs

Lonza to Buy Genentech’s Vacaville, CA Biologics Manufacturing Site for $1.2B
Bioprocessing

Lonza to Buy Genentech’s Vacaville, CA Biologics Manufacturing Site for $1.2B

WuXi Biologics Launches New Bioprocessing Platform
Bioprocessing

WuXi Biologics Launches New Bioprocessing Platform

Effective Engineering of Bispecific/Multispecific Antibodies for Biotherapeutics Development
Bioprocessing

Effective Engineering of Bispecific/Multispecific Antibodies for Biotherapeutics Development

Top 10 Contract Development and Manufacturing Organizations
A-Lists

Top 10 Contract Development and Manufacturing Organizations

Prospects for the Oral Delivery of Biopharmaceuticals
Bioprocessing

Prospects for the Oral Delivery of Biopharmaceuticals

1234Page 1 of 4
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.